Cme (CME) EBITDA (2009 - 2026)

Cme (CME) has reported EBITDA for 18 consecutive years, with $1.1 billion the latest figure, recorded in Q2 2026.

• Quarterly EBITDA fell 1.97% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.4 billion (up 4.76% YoY) and the FY2025 annual result came in at $4.2 billion, up 7.58% from the prior year.
• EBITDA eased to $1.1 billion in Q2 2026 per CME's latest filing, from $1.3 billion in the prior quarter.
• Over the last five years, EBITDA for CME reached as high as $1.3 billion in Q1 2026 and fell as low as $668.3 million in Q4 2022.
• A 5-year average of $946.1 million and a median of $953.4 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA gained 29.16% — and 2025, when it decreased 5.04%.
• Year by year, EBITDA stood at $668.3 million in 2022, then increased by 29.16% to $863.2 million in 2023, then gained by 9.72% to $947.1 million in 2024, then advanced by 7.65% to $1.0 billion in 2025, then increased by 8.58% to $1.1 billion in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $1.1 billion, $1.3 billion, and $1.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.